{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:46:49Z","timestamp":1784216809170,"version":"3.55.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.drudis.2022.02.017","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T22:00:12Z","timestamp":1645653612000},"page":"1706-1715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world data in drug development strategies for orphan drugs: Tafasitamab in B-cell lymphoma, a case study for an approval based on a single-arm combination trial"],"prefix":"10.1016","volume":"27","author":[{"given":"Philippe","family":"Serrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiu Wah","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Akdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Reinholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Peltier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Ligensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Seiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achta","family":"Paraiso Le Bourhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.02.017_b0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(02)07283-5","article-title":"An overview of clinical research: the lay of the land","volume":"59","author":"Grimes","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.drudis.2022.02.017_b0010","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005\u20132012","volume":"311","author":"Downing","year":"2014","journal-title":"JAMA."},{"key":"10.1016\/j.drudis.2022.02.017_b0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3284","article-title":"Assessment of clinical trials supporting US Food and Drug Administration approval of novel therapeutic agents, 1995\u20132017","volume":"3","author":"Zhang","year":"2020","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.drudis.2022.02.017_b0020","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/cpt.86","article-title":"The role of nonrandomized trials in the evaluation of oncology drugs","volume":"97","author":"Simon","year":"2015","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.drudis.2022.02.017_b0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011666","article-title":"Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999\u20132014","volume":"6","author":"Hatswell","year":"2016","journal-title":"BMJ Open."},{"key":"10.1016\/j.drudis.2022.02.017_b0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11111","article-title":"US Food and Drug Administration approvals of drugs and devices based on nonrandomized clinical trials: a systematic review and meta-analysis","volume":"2","author":"Razavi","year":"2019","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.drudis.2022.02.017_b0035","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1001\/jama.2011.769","article-title":"Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer","volume":"305","author":"Kesselheim","year":"2011","journal-title":"JAMA."},{"key":"10.1016\/j.drudis.2022.02.017_b0040","unstructured":"Pignatti F, Demolis P. Targeting \u2018histology-independent indications\u2019 and resulting challenges in the context of orphan designations. 4th EMA Industry Stakeholder Platform on R&D Support. www.ema.europa.eu\/en\/documents\/presentation\/presentation-targeting-histology-independent-indications-resulting-challenges-context-orphan_en-0.pdf [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0045","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/cts.12667","article-title":"Precision medicines\u2019 impact on orphan drug designation","volume":"12","author":"Mueller","year":"2019","journal-title":"Clin Transl Sci."},{"key":"10.1016\/j.drudis.2022.02.017_b0050","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jama.2018.10136","article-title":"Real-world evidence and real-world data for evaluating drug safety and effectiveness","volume":"320","author":"Corrigan-Curay","year":"2018","journal-title":"JAMA."},{"key":"10.1016\/j.drudis.2022.02.017_b0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cpt.1426","article-title":"Real-world data for regulatory decision making: challenges and possible solutions for Europe","volume":"106","author":"Cave","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.drudis.2022.02.017_b0060","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/cpt.1351","article-title":"Evaluating the use of nonrandomized real-world data analyses for regulatory decision making","volume":"105","author":"Franklin","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.drudis.2022.02.017_b0065","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/pds.4932","article-title":"Trial designs using real-world data: The changing landscape of the regulatory approval process","volume":"29","author":"Baumfeld Andre","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.drudis.2022.02.017_b0070","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/pds.4975","article-title":"Real-world evidence to support regulatory decision-making for medicines: considerations for external control arms","volume":"29","author":"Burcu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.drudis.2022.02.017_b0075","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/cpt.1723","article-title":"Beyond randomized clinical trials: use of external controls","volume":"107","author":"Schmidli","year":"2020","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.drudis.2022.02.017_b0080","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cpt.2083","article-title":"Randomized controlled trials versus real world evidence: neither magic nor myth","volume":"109","author":"Eichler","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.drudis.2022.02.017_b0085","unstructured":"FDA. FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma. www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma [Accessed February 18, 2021]."},{"key":"10.1016\/j.drudis.2022.02.017_b0090","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2022.02.017_b0095","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1158\/1078-0432.CCR-21-1471","article-title":"RE-MIND: comparing tafasitamab + lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma","volume":"27","author":"Zinzani","year":"2021","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.drudis.2022.02.017_b0100","unstructured":"EMA. CHMP summary of positive opinion for Monjivi. www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion\u2013minjuvi_en.pdf. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0105","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1158\/1078-0432.CCR-20-3292","article-title":"Project Orbis: global collaborative review program","volume":"26","author":"de Claro","year":"2020","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.drudis.2022.02.017_b0110","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-020-01405-w","article-title":"Tafasitamab: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs."},{"key":"10.1016\/j.drudis.2022.02.017_b0115","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.4049\/jimmunol.1201000","article-title":"A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice","volume":"189","author":"Poe","year":"2012","journal-title":"J Immunol."},{"key":"10.1016\/j.drudis.2022.02.017_b0120","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/d41573-019-00167-9","article-title":"Immuno-oncology drug development goes global","volume":"18","author":"Xin","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.drudis.2022.02.017_b0125","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2022.02.017_b0130","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","article-title":"CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody","volume":"115","author":"Awan","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.drudis.2022.02.017_b0135","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1200\/jco.2012.30.15_suppl.6574","article-title":"Evaluation of combination therapies with MOR00208, an Fc-enhanced humanized CD19 antibody, in models of lymphoma","volume":"30: 15_suppl","author":"Winderlich","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.drudis.2022.02.017_b0140","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2014-11-567792","article-title":"Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities","volume":"125","author":"Kritharis","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.drudis.2022.02.017_b0145","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.drudis.2022.02.017_b0150","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2014-08-593269","article-title":"A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL","volume":"124","author":"Woyach","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.drudis.2022.02.017_b0155","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol."},{"key":"10.1016\/j.drudis.2022.02.017_b0160","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/14712598.2021.1884677","article-title":"Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Salles","year":"2021","journal-title":"Expert Opin Biol Ther."},{"issue":"Supplement 1","key":"10.1016\/j.drudis.2022.02.017_b0165","first-page":"4123","article-title":"Single-arm Phase II study of MOR208 combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: L-mind","volume":"130","author":"Salles","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2022.02.017_b0170","unstructured":"FDA. Guidance for Industry: codevelopment of two or more new investigational drugs for use in combination. www.fda.gov\/media\/80100\/download. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0175","unstructured":"EMA. Guideline on the evaluation of anticancer medicinal products in man, Revision 4. www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-anticancer-medicinal-products-man-revision-4_en.pdf. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0180","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/d41573-019-00066-z","article-title":"Novel-novel fixed-dose combination therapies","volume":"18","author":"Carter","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.drudis.2022.02.017_b0185","first-page":"904","article-title":"Stribild: a review of component characteristics and combination drug efficacy","volume":"19","author":"Murrell","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"10.1016\/j.drudis.2022.02.017_b0190","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist."},{"key":"10.1016\/j.drudis.2022.02.017_b0195","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-13-2054","article-title":"Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma","volume":"20","author":"Menzies","year":"2014","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.drudis.2022.02.017_b0200","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","article-title":"Encorafenib and binimetinib: first global approvals","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs."},{"key":"10.1016\/j.drudis.2022.02.017_b0205","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJMc1700103","article-title":"Regulatory review of new therapeutic agents - FDA versus EMA, 2011\u20132015","volume":"376","author":"Downing","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.drudis.2022.02.017_b0210","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cpt.1123","article-title":"Clinical development and initial approval of novel immune checkpoint inhibitors in oncology: insights from a global regulatory perspective","volume":"105","author":"Serrano","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.drudis.2022.02.017_b0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/cpt.1","article-title":"FDA designations for therapeutics and their impact on drug development and regulatory review outcomes","volume":"97","author":"Kesselheim","year":"2015","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.drudis.2022.02.017_b0220","article-title":"Trends in utilization of FDA expedited drug development and approval programs, 1987\u20132014: cohort study","volume":"351","author":"Kesselheim","year":"2015","journal-title":"BMJ."},{"key":"10.1016\/j.drudis.2022.02.017_b0225","doi-asserted-by":"crossref","unstructured":"Pregelj L, Hine DC, Kesselheim AS, Darrow JJ. Assessing the impact of US Food and Drug Administration breakthrough therapy designation timing on trial characteristics and development speed. Clin Pharmacol Ther. 202; 110: 1018\u20131024.","DOI":"10.1002\/cpt.2318"},{"key":"10.1016\/j.drudis.2022.02.017_b0230","unstructured":"CDER. Multidiscipline Review BLA761163Orig1 (Monjuvi). www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/761163Orig1s000MultidisciplineR.pdf. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0235","unstructured":"Doherty K. Phase 3 Front-MIND trial initiated to explore Tafasitamab triplet in DLBCL. www.targetedonc.com\/view\/phase-3-front-mind-trial-initiated-to-explore-tafasitamab-triplet-in-dlbcl. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0240","unstructured":"FDA. Framework for FDA\u2019s real-world evidence program. www.fda.gov\/media\/120060\/download. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0245","unstructured":"FDA Draft Guidance for Industry. Submitting documents using real-world data and real-world evidence to FDA for drugs and biologics. www.fda.gov\/media\/124795\/download. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0250","unstructured":"FDA Guidance for Industry. Real-world data: assessing electronic health records and medical claims data to support regulatory decision making for drug and biological products. www.fda.gov\/media\/152503\/download. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0255","unstructured":"FDA Draft Guidance for Industry. Data standards for drug and biological product submissions containing real-world Data. www.fda.gov\/media\/153341\/download. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0260","unstructured":"FDA Draft Guidance for Industry. Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products. www.fda.gov\/media\/154714\/download. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0265","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/cpt.1226","article-title":"Data rich, information poor: can we use electronic health records to create a learning healthcare system for pharmaceuticals?","volume":"105","author":"Eichler","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.drudis.2022.02.017_b0270","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cpt.1638","article-title":"Are novel, nonrandomized analytic methods fit for decision making? The need for prospective, controlled, and transparent validation","volume":"107","author":"Eichler","year":"2020","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.drudis.2022.02.017_b0275","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jval.2020.04.002","article-title":"Improving transparency to build trust in real-world secondary data studies for hypothesis testing-why, what, and how: recommendations and a road map from the real-world evidence transparency initiative","volume":"23","author":"Orsini","year":"2020","journal-title":"Value Health."},{"key":"10.1016\/j.drudis.2022.02.017_b0280","unstructured":"EMA. European Public Assessment Report MINJUVI. www.ema.europa.eu\/en\/documents\/assessment-report\/minjuvi-epar-public-assessment-report_en.pdf. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0285","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1468-0009.12476","article-title":"Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States","volume":"98","author":"Salcher-Konrad","year":"2020","journal-title":"Milbank Q."},{"key":"10.1016\/j.drudis.2022.02.017_b0290","unstructured":"EU. Commission Regulation (EC) No 507\/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726\/2004 of the European Parliament and of the Council. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX: 32006R0507&from=IT. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0295","unstructured":"EMA. Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No 507\/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726\/2004. www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-scientific-application-practical-arrangements-necessary-implement-commission-regulation-ec\/2006-conditional-marketing-authorisation-medicinal-products-human-use-falling_en.pdf. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0300","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.drudis.2020.04.012","article-title":"Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations","volume":"25","author":"Vreman","year":"2020","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.drudis.2022.02.017_b0305","article-title":"Defining satisfactory methods of treatment in rare diseases when evaluating significant benefit\u2013the EU regulator\u2019s perspective","volume":"8","author":"Sheean","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.drudis.2022.02.017_b0310","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.drudis.2022.02.017_b0315","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0266462319000333","article-title":"Population Adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence technology appraisals","volume":"35","author":"Phillippo","year":"2019","journal-title":"Int J Technol Assess Health Care."},{"key":"10.1016\/j.drudis.2022.02.017_b0320","unstructured":"EMA. Orphan Maintenance Assessment Report. www.ema.europa.eu\/en\/documents\/orphan-maintenance-report\/minjuvi-orphan-maintenance-assessment-report-initial-authorisation_en.pdf. [Accessed February 24, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0325","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024895","article-title":"Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review","volume":"9","author":"Goring","year":"2019","journal-title":"BMJ Open."},{"key":"10.1016\/j.drudis.2022.02.017_b0330","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jval.2020.06.006","article-title":"Use of real-world evidence to support FDA approval of oncology drugs","volume":"23","author":"Feinberg","year":"2020","journal-title":"Value Health."},{"key":"10.1016\/j.drudis.2022.02.017_b0335","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.84","article-title":"Blinatumomab vs historical standard therapy of adult relapsed\/refractory acute lymphoblastic leukemia","volume":"6","author":"G\u00f6kbuget","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drudis.2022.02.017_b0340","unstructured":"EMA. European Public Assessment Report ZALMOXIS www.ema.europa.eu\/en\/documents\/assessment-report\/zalmoxis-epar-public-assessment-report_en.pdf. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0345","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.drudis.2022.02.017_b0350","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1634\/theoncologist.2019-0646","article-title":"EMA review of axicabtagene ciloleucel (Yescarta) for the treatment of diffuse large B-cell lymphoma","volume":"25","author":"Papadouli","year":"2020","journal-title":"Oncologist."},{"key":"10.1016\/j.drudis.2022.02.017_b0355","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","article-title":"The European Medicines Agency review of Kymriah (tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma","volume":"25","author":"Ali","year":"2020","journal-title":"Oncologist."},{"key":"10.1016\/j.drudis.2022.02.017_b0360","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/pds.5141","article-title":"Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials","volume":"29","author":"Seeger","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.drudis.2022.02.017_b0365","unstructured":"MHLW. Basic principles on utilization of Registry (data) for Applications. www.pmda.go.jp\/files\/000240810.pdf. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0370","unstructured":"Australian Therapeutic Goods Administration (TGA). Real world evidence and patient reported outcomes in the regulatory context. www.tga.gov.au\/sites\/default\/files\/real-world-evidence-and-patient-reported-outcomes-in-the-regulatory-context.pdf. [Accessed February 18, 2022]."},{"key":"10.1016\/j.drudis.2022.02.017_b0375","article-title":"Integrating real-world evidence in the regulatory decision\u2013making process: a systematic analysis of experiences in the US, EU, and China using a logic model","volume":"8","author":"Li","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.drudis.2022.02.017_b0380","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpt.2479","article-title":"Real-world evidence in EU medicines regulation: enabling use and establishing value","volume":"111","author":"Arlett","year":"2022","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.drudis.2022.02.017_b0385","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cpt.2461","article-title":"Marketing authorization applications made to the European Medicines Agency in 2018\u20132019: what was the contribution of real-world evidence?","volume":"111","author":"Flynn","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.drudis.2022.02.017_b0390","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/1078-0432.CCR-21-2639","article-title":"Real-world evidence in support of oncology product registration: a systematic review of new drug application and biologics license application approvals from 2015\u20132020","volume":"28","author":"Arondekar","year":"2022","journal-title":"Clin Cancer Res."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622000757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622000757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:00:33Z","timestamp":1761224433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622000757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1359644622000757"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.02.017","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world data in drug development strategies for orphan drugs: Tafasitamab in B-cell lymphoma, a case study for an approval based on a single-arm combination trial","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}